These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33903963)

  • 1. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study.
    Maeda Y; Hirano T; Ebina K; Hara R; Hashimoto M; Yamamoto W; Murakami K; Kotani T; Hata K; Son Y; Amuro H; Onishi A; Jinno S; Katayama M; Kumanogoh A
    Rheumatol Int; 2021 Jul; 41(7):1233-1241. PubMed ID: 33903963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in the treatment of adult rheumatoid arthritis.
    Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
    Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
    Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
    Watanabe R; Ebina K; Gon T; Okano T; Murata K; Murakami K; Maeda Y; Jinno S; Shirasugi I; Son Y; Amuro H; Katayama M; Hara R; Hata K; Yoshikawa A; Yamamoto W; Tachibana S; Hayashi S; Etani Y; Katsushima M; Fukumoto K; Yamada S; Hashimoto M
    Rheumatology (Oxford); 2024 Sep; 63(9):2418-2426. PubMed ID: 38724245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
    Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
    Yoshimura Y; Yamanouchi M; Mizuno H; Ikuma D; Koizumi R; Kurihara S; Oba Y; Suwabe T; Sawada Y; Kamido H; Sugimoto H; Mizuta M; Sekine A; Hasegawa E; Ubara Y; Sawa N
    Ann Rheum Dis; 2024 Sep; 83(10):1278-1287. PubMed ID: 38964755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
    Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
    Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.
    Kawashiri SY; Nishino A; Shimizu T; Umeda M; Fukui S; Nakashima Y; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Kawakami A
    Mod Rheumatol; 2017 Mar; 27(2):252-256. PubMed ID: 27585858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis.
    Hasegawa E; Ito S; Kurosawa Y; Kobayashi D; Otani H; Abe A; Nakazono K; Murasawa A; Narita I; Ishikawa H
    Intern Med; 2023; 62(3):373-379. PubMed ID: 36725065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Have the radiographic characteristics of total knee arthroplasty recipients in rheumatoid arthritis changed after the induction of biologic disease modifying antirheumatic drugs?
    Fujimura K; Haraguchi A; Sakurai R; Kamura S; Sakuraba K; Miyahara H; Fukushi JI
    Mod Rheumatol; 2022 Oct; 32(6):1047-1053. PubMed ID: 34850099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.
    Shirasugi I; Onishi A; Nishimura K; Yamamoto W; Murakami K; Onizawa H; Maeda Y; Ebina K; Son Y; Amuro H; Katayama M; Hara R; Nagai K; Hiramatsu Y; Hashimoto M; Okano T; Maeda T; Hayashi S; Sendo S; Jinno S; Yamamoto Y; Yamada H; Ueda Y; Saegusa J
    Int J Rheum Dis; 2024 Mar; 27(3):e15097. PubMed ID: 38439176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis.
    Murata K; Uozumi R; Fujii T; Onishi A; Murakami K; Onizawa H; Tanaka M; Morinobu A; Matsuda S
    Sci Rep; 2024 Jul; 14(1):15226. PubMed ID: 38956271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study.
    Terabe K; Takahashi N; Asai S; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Ishikawa H; Hanabayashi M; Hattori Y; Suzuki M; Kishimoto K; Ohashi Y; Imaizumi T; Imagama S; Kojima T
    Mod Rheumatol; 2023 Aug; 33(5):891-898. PubMed ID: 35975317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
    Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
    Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.